Publication details

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Authors

CLEMENS Eva VAN DEN HEUVEL-EIBRINK Marry M. MULDER Renée L. KREMER Leontien C. M. HUDSON Melissa M. SKINNER Roderick CONSTINE Louis S. BASS Johnnie K. KUEHNI Claudia E. LANGER Thorsten VAN DALEN Elvira C. BARDI Edith BONNE Nicolas-Xavier BROCK Penelope R BROOKS Beth CARLETON Bruce CARON Eric CHANG Kay W JOHNSTON Karen KNIGHT Kristin NATHAN Paul C. ORGEL Etan PRASAD Pinki K. ROTTENBERG Jan SCHEINEMANN Katrin DE VRIES Andrica C. H. WALWYN Thomas WEISS Annette ZEHNHOFF-DINNESEN Antoinette am COHN Richard J LANDIER Wendy

Year of publication 2019
Type Article in Periodical
Magazine / Source The Lancet Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30858-1/fulltext
Doi http://dx.doi.org/10.1016/S1470-2045(18)30858-1
Keywords ototoxicity; surveillance; guidelines; childhood adolescent and young adults cancer survivors
Attached files
Description Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

You are running an old browser version. We recommend updating your browser to its latest version.

More info